American House Dust Mite (Der f 18) IgE

Picture someone whose nose runs every morning, whose eczema flares after changing the sheets, and whose standard dust mite blood test has already come back positive. The useful next question is how broad that allergy has become, because people who react to many mite proteins tend to have more persistent disease than people who react to one or two.

Der f 18 is allergen group 18 from Dermatophagoides farinae. That species is often called the American house dust mite. Together with the European house dust mite, it accounts for most dust mite allergy worldwide. This blood test reports IgE to Der f 18. It is a specialized component marker used mainly in research and detailed component panels. It is not a routine or stand-alone test for ruling dust mite allergy in or out, so it works best as one piece of a larger mite allergy pattern.

A Less Common Mite Protein

IgE is the antibody behind allergic reactions. Your immune system makes a separate version for each protein it has learned to treat as a threat, and this test measures the version aimed at Der f 18.

Der f 18 is a mite protein related to chitinases, a family of proteins that help organisms handle chitin. Chitin is the tough material found in mite and insect shells. The original Der f 18 study found the protein in the mite digestive system but did not detect it in fecal pellets. That sets it apart from the group 1 and group 3 allergens, which are concentrated in mite droppings.

Groups 1 and 2, Der f 1 and Der f 2 in this species, carry most of the IgE response in dust mite allergy. Group 18 is treated as a minor or mid-tier component in human component testing, and published recognition rates vary a lot by population and by test method. In the original study, purified Der f 18 bound IgE in 54% of sera from a selected group of people with D. farinae allergy and in most sensitized dogs, which is why its discoverers called it a major allergen for humans and dogs. It has stood out most in dogs with allergic skin disease. In a German birth cohort that measured the European mite version, Der p 18, fewer than 1 in 10 mite-sensitized participants reacted to it by age 20.

A detectable level means sensitization. Your immune system has made IgE against that protein. Whether it is causing your symptoms is a separate question, and the rest of this page is about how to answer it without overreading a single component.

How Mite Allergy Broadens

Mite allergy often builds in a sequence. In a birth cohort of 722 children followed to age 20, IgE responses started against the major Dermatophagoides pteronyssinus proteins, mainly groups 1, 2, and 23, and then expanded to other proteins over the years. Group 18 appeared late and stayed uncommon. That study measured Der p 18, a close relative of Der f 18, so it is useful context rather than direct evidence for this exact test.

This is why a group 18 result is mainly a breadth marker. If Der f 18 is positive along with whole D. farinae extract, Der f 1, Der f 2, and related D. pteronyssinus components, the pattern suggests an established mite response that has moved beyond the usual starting proteins.

Broadening mattered in that birth cohort. Children whose IgE spread across many mite proteins were more likely to have mite-related nasal allergy at the same time and asthma later. Early mite exposure and parental hay fever were linked with a broader pattern.

Eczema and Skin Disease

Eczema shows one of the clearer links to broad mite component sensitization, though most studies are about panels of mite proteins rather than Der f 18 alone. In a study of 160 people with mite allergy, those with atopic dermatitis reacted to more minor mite proteins than people whose allergy affected only the nose and lungs.

A study of 384 people with mite allergy found a similar pattern. People whose disease was mainly eczema reacted to more mite proteins than people without eczema, and the number of proteins someone reacted to helped describe how severe their disease was.

Mite sensitization also shows up early in some children with skin disease. Among 1,793 children under two, those already sensitized to whole dust mite extract had more eczema and more food allergy. Whole extract is a broader measurement than this single-protein result.

What this means for you: if you have eczema that flares indoors or won't settle with good skin care, a positive Der f 18 alongside other mite components fits the broader pattern seen in eczema-predominant disease. It should push you to read the full component profile, not to treat Der f 18 as the cause by itself.

Nasal Allergy and Asthma

For the nose and lungs, the major proteins still carry most of the signal. In children with mite-driven disease, Der p 2, Der f 2, and Der p 23 were the components most closely tied to respiratory allergy and asthma. Asthmatic children with mite allergy also tended to have IgE spread across more mite proteins, and at higher levels, than allergic children without asthma.

What this means for you: in someone with asthma or year-round nasal symptoms, a positive Der f 18 reads best as a sign of breadth. It suggests the immune response has expanded, while the major components remain the better-supported airway markers.

When Results Can Be Misleading

The biggest source of misreading is treating a positive result as proof of allergy. A few other factors can also make a single number look more or less meaningful than it is.

• Sensitization without symptoms: many people carry mite IgE without reacting clinically. When mite sensitization tests were checked against nasal challenge, a positive result did not always match a true nasal reaction.
• Very high total IgE: people with high overall allergy antibody levels, common with severe eczema or several allergic conditions at once, can show higher readings across many specific tests.
• Different lab platforms: single-allergen blood tests and multi-allergen chip tests do not report interchangeable numbers. Use the same lab and platform when comparing results over time.
• Different mite species: Der f 18 and Der p 18 are related but not identical. Evidence from Der p 18 can help interpret this result, but it is not direct evidence about Der f 18.
• Symptoms confined to the nose: some people make mite IgE mainly in nasal tissue. Blood tests can miss that pattern.

Antihistamines don't affect blood IgE tests the way they blunt skin prick tests, and meals or time of day don't shift the result in a meaningful way. Rare lab-specific factors can still affect a reading, which is why an unexpected result is worth repeating on the same platform before you act on it.

Tracking Your Number Over Time

Because this is a research-stage component without population cutpoints, a single number tells you less than the pattern around it. Get a baseline if you are mapping a known mite allergy, then retest only when the result will change a decision, such as before and after a long stretch of immunotherapy. Use the same lab and testing platform each time.

Two long-term patterns matter. First, sensitization can fade with age in some people. In 51 people followed over time, IgE to individual mite proteins declined as they got older, with a suggestion of milder nasal and asthma symptoms. Second, allergy immunotherapy can improve symptoms without making component IgE fall much.

During immunotherapy, the number and the symptoms can move separately. IgE reflects how primed your immune system is. Immunotherapy also raises blocking antibodies that can intercept allergen before it reaches IgE. Symptoms can improve while Der f 18 stays flat, so judge progress by symptoms, medication use, and the broader component pattern.

What to Do With a Positive Result

Start by placing Der f 18 in context. Check whether you also react to the whole D. farinae extract and to the major proteins Der f 1, Der f 2, and Der p 23, and add total IgE to see whether your overall allergy antibody level is high. Then match the pattern to your symptoms.

• Major proteins plus Der f 18 positive: this fits a broader, established mite sensitization pattern. With symptoms, it is reasonable to discuss immunotherapy with an allergist.
• Der f 18 positive, major proteins negative: this is unusual. Retest on the same platform and consider whether the result reflects cross-reactivity or a platform-specific signal before treating it as the main explanation.
• Symptoms with negative blood tests: some people make mite IgE only in the lining of the nose. Nasal secretion testing or a supervised nasal challenge can pick this up when blood tests can't.
• Wheezing or chest tightness: add lung function testing and a blood eosinophil count. Eosinophils are white blood cells that rise with allergic inflammation, and exhaled nitric oxide can help show whether the airways are inflamed.

An allergist is the right partner once you're weighing immunotherapy or need a nasal or bronchial challenge, since those require supervision and, for immunotherapy, a prescription. Everything before that point, including the component panel and total IgE, you can order and read as part of your own pattern.